These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 17718223)
21. Points to consider: the roles of surveillance and epidemiology in advancing drug safety. Edwards R; Faich G; Tilson H; Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):665-7. PubMed ID: 15719353 [No Abstract] [Full Text] [Related]
22. [A literature review of adverse drug reaction reports. Adverse drug effects can have genetical background]. Rane A Lakartidningen; 2002 May; 99(20):2266-7. PubMed ID: 12082942 [No Abstract] [Full Text] [Related]
23. Improving pharmacovigilance in Europe. Moore N; Bégaud B BMJ; 2010 Apr; 340():c1694. PubMed ID: 20385717 [No Abstract] [Full Text] [Related]
30. Unusual and severe forms of adverse drug reactions. Gogtay N; Mangalvedhekar S; Kshirsagar NA J Assoc Physicians India; 1999 Aug; 47(8):847. PubMed ID: 10778648 [No Abstract] [Full Text] [Related]
31. Adverse drug reaction reporting--1998. Sutcliffe H CMAJ; 1999 Apr; 160(7):1051, 1055. PubMed ID: 10207351 [No Abstract] [Full Text] [Related]
32. European commission consultation on pharmacovigilance. Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839 [No Abstract] [Full Text] [Related]
33. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. Glasser SP; Salas M; Delzell E J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697 [TBL] [Abstract][Full Text] [Related]
34. Detection of adverse reactions to new medicines. Griffin JP Adverse Drug React Toxicol Rev; 1996 Jun; 15(2):77-8. PubMed ID: 8836313 [No Abstract] [Full Text] [Related]
35. Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel. Macedo AF; Marques FB; Ribeiro CF; Teixeira F Pharmacoepidemiol Drug Saf; 2005 Dec; 14(12):885-90. PubMed ID: 16059869 [TBL] [Abstract][Full Text] [Related]
36. The Welsh Adverse Drug Reactions Scheme: experience of a UK regional monitoring centre. Houghton JE; Pinto Pereira LM; Woods FJ; Richens A; Routledge PA Adverse Drug React Toxicol Rev; 1996 Jun; 15(2):93-107. PubMed ID: 8836315 [No Abstract] [Full Text] [Related]
37. The national registry of drug-induced ocular side effects. Fraunfelder FT; Meyer SM Aust J Ophthalmol; 1984 May; 12(2):129-31. PubMed ID: 6487182 [TBL] [Abstract][Full Text] [Related]
38. Rethinking the numbers on adverse drug reactions. Lexchin J CMAJ; 1999 May; 160(10):1432. PubMed ID: 10352628 [No Abstract] [Full Text] [Related]
39. Advances in the pharmacogenomics of adverse drug reactions. Alvarado I; Wong ML; Licinio J Pharmacogenomics J; 2002; 2(5):273. PubMed ID: 12439730 [No Abstract] [Full Text] [Related]
40. Monitoring for adverse drug events. Kennedy DL; Goldman SA Am Fam Physician; 1997 Nov; 56(7):1718, 1721. PubMed ID: 9371003 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]